A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

Am J Hematol. 2018 Aug;93(4):E96-E98. doi: 10.1002/ajh.25035. Epub 2018 Feb 5.

Abstract

NCT01246206. The study was approved by Wayne State University Institutional Review Board.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Allografts
  • Antilymphocyte Serum / therapeutic use*
  • Disease-Free Survival
  • Family
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / prevention & control*
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Living Donors
  • Lymphocyte Transfusion
  • Male
  • Middle Aged
  • Tacrolimus / therapeutic use*
  • Treatment Failure

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • thymoglobulin
  • Tacrolimus